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Abstract
Background: Obesity has been reported as an adverse prognostic factor in breast cancer, but inconsistently, and
under-treatment with chemotherapy may occur. We provide the first assessment of obesity and breast cancer
outcomes in a population-based, multi-ethnic cohort of New Zealand patients treated with chemotherapy.
Methods: All 3536 women diagnosed with invasive breast cancer in the Waikato region of New Zealand from
2000-2014 were registered and followed until last follow-up in specialist or primary care, death or Dec 2014;
median follow-up 4.1 years. For the 1049 patients receiving chemotherapy, mortality from breast cancer, other
causes, and all causes, and rates of loco-regional and of distant recurrence, were assessed by body mass index
(BMI), recorded after diagnosis, adjusting for other clinico-pathological and demographic factors by Cox regression.
Results: BMI was known for 98% (n=1049); 33% were overweight (BMI 25-29.9), 21% were obese (BMI 30-34.9), and
14% were very obese (BMI 35+). There were no significant associations between obesity and survival, after
adjustment for demographic and clinical factors (hazard ratios, HR, for very obese compared to BMI 21-24, for breast
cancer deaths 0.96 (0.56-1.67), and for all deaths 1.03 (0.63-1.67), respectively, and only small non-significant
associations for loco-regional or metastatic recurrence rates (HR 1.17 and 1.33 respectively). Subgroup analyses by
age, menopausal status, ethnicity, stage, post-surgical radiotherapy, mode of diagnosis, type of surgery, and
receptor status, showed no associations. No associations were seen with BMI as a continuous variable. The results in
all patients irrespective of treatment but with recorded BMI data (n=2296) showed similar results.
Conclusions: In this population, obesity assessed post-diagnosis had no effect on survival or recurrence, based on
1049 patients with chemotherapy treatment with follow-up up to 14 years.
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Background
Obesity is generally accepted as an adverse prognostic
factor in breast cancer. A meta-analysis of 82 studies
reported an increased risk of breast cancer mortality,
hazard ratio 1.35 (95% limits 1.24-1.47) for ‘obese’
women (body mass index (BMI) 30+) compared to those
with a ‘normal’ BMI (18.5 to 25) [1], seen in both pre-
and post-menopausal women. This meta-analysis
showed significant publication bias, suggesting that some
small studies with null or inverse results have not been
published. Many studies are based on incomplete or
selective data: for example, one of the largest studies
excluded 65% of otherwise eligible patients as they had
no data on BMI recorded [2].
Several mechanisms have been suggested by which
obesity could affect breast cancer prognosis; biological
mechanisms influencing tumour progression; interac-
tions with therapies; and health care-related issues
affecting treatment and diagnosis.
Obesity is associated with elevated levels of serum
oestrogen, produced by conversion of androgens by
aromatase in adipose fat [3], and lower levels of sex
hormone-binding globulin, which lowers oestrogenic
activity [4]. Obesity is associated with higher levels of
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insulin and the adipocyte derived cytokine leptin [5] and
could have effects related to markers of inflammation
[6]. Effects through these mechanisms would be
expected to be greater in post-menopausal women; how-
ever, in the meta-analysis noted no difference in effects
by menopausal status was seen [1]. Breast cancer
patients who are obese have been shown to have greater
expression of proliferation genes [7], and faster growing
tumours as assessed by Ki-67 [8].
These hormonal-based mechanisms suggest that anti-
oestrogenic therapy might be of greater benefit to obese
women. This has not been shown for tamoxifen [9], but
a greater benefit from raloxifene in women with higher
BMI has been suggested [10]. Obese women may have a
reduced response to aromatase inhibitors [11, 12]. While
the efficacy of full doses of chemotherapy does not
appear to be affected by obesity [9, 13], obese women
are likely to receive sub-optimal dosages of chemother-
apy [14–16]. In one study in a patient population with a
high prevalence of obesity, practice standards to avoid
under-dosing are suggested as the reason why no effects
of BMI on outcomes were seen [17].
Obese women may be disadvantaged at diagnosis; they
may have larger primary tumours, more positive lymph
nodes, and more advanced stage [18], and they may be
less likely to be diagnosed by screening [19]. The associ-
ation between BMI and breast cancer outcome may vary
in women of different ethnic groups [20]. A stronger
adverse effect of obesity on breast cancer survival in
women of Asian ancestry has been shown in some
studies [21, 22].
In this study, we assessed associations between breast
cancer-specific and overall survival, and recurrence, with
BMI in a large population-based cohort of women with
breast cancer in New Zealand (NZ). Patients were diag-
nosed between January 2000 and June 2014 and followed
to last follow up, death, or Dec 2016 or to death; median
follow up 4.1 years. We restricted the main analysis to
the 1049 patients with stage 1 to 4 breast cancer who re-
ceived chemotherapy as part of their primary treatment;
98% had data on BMI collected after diagnosis but before
systemic treatment. We were able to take into account
age, menopausal status, ethnicity, social deprivation, co-
morbidity, mode of diagnosis, staging, grade, and receptor
status, and primary treatment. We also assessed the out-
comes in all 2296 patients, irrespective of treatment, who
had known BMI data.
Methods
Eligible cohort
There were 3536 women resident in the Waikato region,
New Zealand, who had breast cancer diagnosed between
Jan 1, 2000 to 30 June 2014, of which 3065 had invasive
disease (Fig. 1). For the main analysis, eligible women
were the 1067 who had chemotherapy as part of their
primary treatment. Of these 1049 (98%, all but 18) had
information on height and weight before systemic treat-
ment and were included in our main analysis. These
patients were enrolled on the Waikato clinical breast
cancer register and followed actively to the date of death
or to last follow-up. For patients who had completed
hospital-based follow up, primary care follow-up was
documented. Median follow-up time was 4.1 years. The
registry is linked to national mortality data and to the
legally-mandated national cancer registry to ensure com-
pleteness [23], and to other hospital discharge data to
assess co-morbidity. Recurrences were documented on
regular hospital follow-up, or for patients discharged
from regular hospital follow up, information from the
primary care or private practice physician updated
annually or more frequently. A secondary analysis was
done on the outcomes for all 2296 women with invasive
cancer who had BMI data recorded.
Data
Height and weight were recorded at the first clinic visit
after diagnosis and before primary treatment or after
primary surgery but before systemic treatment; BMI was
calculated as weight, kg/height,m2. Patient ethnicity was
identified from the breast cancer registries or where not
available from the national cancer registry or mortality
data, following NZ Ministry of Health ethnicity data
protocols [24]. Ethnicity was categorized into NZ
European, Māori, Pacific, and Other. Socioeconomic
deprivation was classified according to the New Zealand
Deprivation Index 2006 [25]. This assigns small residen-
tial areas a deprivation decile on a scale of 1 to 10 based
on nine socio-economic variables measured during the
2006 population census; decile1-least deprived, decile
10-most deprived. Urban/rural residential status of each
woman was categorized into main urban, or other
urban (independent or satellite urban) and rural,
based on the New Zealand Statistics urban/rural clas-
sification system [26].
Cancer stage at diagnosis was defined according to the
Tumour, Node, and Metastasis (TNM) system [27]. In-
vasive tumour grade was defined according to the Elston
and Ellis modified Scarff-Bloom-Richardson breast can-
cer grading system [28]. Estrogen (ER) and progesterone
(PR) receptor status was based on the results of immu-
nohistochemistry tests and classified as positive with 1%
or more receptor positive cells [29], although in years
before 1999 values of 10% or more may have been used.
HER-2 status was based on a Fluorescent In-Situ
Hybridization (FISH) test or when this was not available,
on immunohistochemistry [30]. Co-morbidity was
assessed by the C3 index, using linked hospital data [31].
Menopausal status, cancer treatment variables, and local
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or regional recurrence were based on the reviewed
clinical records. Public or private health facility was
based on the place of primary treatment, usually surgery.
Mortality and cause of death were based on the national
cancer registry data, which incorporates clinical reviews.
Statistical methods
Missing values except for BMI were computed using
multiple imputation with ten complete datasets created
by the Markov chain Monte Carlo method [32], incorp-
orating all baseline characteristics and outcomes. Base-
line data were presented as percentages, and compared
across BMI groups by using chi-square and trend statis-
tics. Cumulative incidences for specific outcomes (breast
cancer specific mortality, overall mortality, death from
other causes, loco-regional recurrence and metastasis) in
the presence of competing risks were computed. For
breast cancer specific mortality, death from other causes
as the first event was considered as a competing risk.
For death from other causes, breast cancer specific death
as the first event was considered as a competing risk.
For loco-regional recurrence and metastasis, death from
any cause as the first event was considered as a compet-
ing risk. Cox proportional hazards regression modelling
[33] was then performed and hazards of the specified
outcomes associated with BMI were assessed. For each
outcome, the proportional hazards assumption was
assessed by cumulative Martingale-based residuals [34].
Hazard ratios (HRs) were adjusted for all baseline
characteristics except HER-2 status (as this was assessed
only after 2006): ethnicity, menopausal status, age, New
Zealand Deprivation score [25], urban-rural status, mode
of diagnosis (screening vs. symptomatic), year of diagno-
sis, stage, grade, histology, hormone receptor status (ER
and PR), local treatment (surgery and radiotherapy),
systemic treatment (chemotherapy, hormonal therapy
and biological treatment), treatment facility (public vs.
private), and C3 comorbidity index [31]. All statistical
tests were two-sided and used a p=0.05 significance
level. All analyses were performed using SAS (release
9.4, SAS Institute, Cary, North Carolina).
Results
Patient features and associations with BMI (patients with
chemotherapy)
BMI was considered in 5 categories (Table 1). By BMI
category, 81 women (7.7%) had BMI below 21 (under-
weight); only 8 women had BMI under 18.5. 250 (23.8%)
had BMI of 21-24.9 (reference category), 349 (33.3%)
had BMI from 25-29 (overweight), 225 (21.4%) had BMI
30-34.9 (obese) and 144 (13.7%) had a BMI of over 35
(very obese). Within the very obese category, 86 (8.2%)
had BMI 35-39; 43 (4.1%) had BMI 40-44; 10 (1.0%) had
BMI 45-49 and 5 (0.5%) BMI 50+.
As shown in Table 1 and Fig. 2, BMI was strongly re-
lated to ethnic background, being higher in Pacific (69%
over BMI 30), and Maori (55% over BMI 30) women
than in NZ Europeans (30%) or other groups (mainly
Asian, 13%). The distribution by BMI differs significantly
between Maori and NZ Europeans and between Pacific
and Europeans (both P values <0.001), but not between
Maori and Pacific (P=0.4).
The proportion of obese (BMI 30+) patients changed
little by age or menopausal status, and did not vary
significantly by year of diagnosis. The proportion obese
increased significantly with lower socio-economic condi-
tions, assessed by the NZ Deprivation Code, from 26%
in the least deprived to 41% in the most deprived
groups. It did not vary significantly by rural or urban
residence. Obesity was associated with having one or
more co-morbid conditions (C3 score 1 or higher).
Obesity was markedly more common in patients treated
in the public health care sector (42%) than in those
treated in the private sector (24%).
Fig. 1 Derivation of patients for study
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Table 1 Patient characteristics by body mass index (BMI, kg/m2) groups
Characteristics Total BMI < 21 BMI 21-24 BMI 25-29 BMI 30-34 BMI 35+ Chi-square % Obese Trend
N % N % N % N % N % N % p-value (BMI 30+) p-value
Total 1049 81 7.7 250 23.8 349 33.3 225 21.4 144 13.7 35.2
Adjuvant treatment
Chemotherapy alone 338 32.2 28 8.3 78 23.1 116 34.3 77 22.8 39 11.5 0.6 34.3
Chemotherapy and hormonal therapy 711 67.8 53 7.5 172 24.2 233 32.8 148 20.8 105 14.8 35.6
Age
<40 132 12.6 16 12.1 34 25.8 34 25.8 30 22.7 18 13.6 0.4 36.4 0.7
40-59 678 64.6 52 7.7 162 23.9 230 33.9 137 20.2 97 14.3 34.5
60+ 239 22.6 13 5.4 54 22.6 85 35.6 58 24.3 29 12.1 36.4
Menopausal status
Pre-menopause 474 45.2 44 9.3 129 27.2 150 31.6 93 19.6 58 12.2 0.06 31.9 0.13
Peri-menopause 65 6.2 0 0.0 16 24.6 22 33.8 18 27.7 9 13.8 41.5
Post-menopause 506 48.2 37 7.3 105 20.8 176 34.8 113 22.3 75 14.8 37.2
Missing/unknown 4 0.4 0 0.0 0 0.0 1 25 1 25.0 2 50.0 75.0
Year of diagnosis
2000-2002 190 18.1 16 8.4 51 26.8 66 34.7 40 21.1 17 8.9 0.5 30.0 0.2
2003-2005 213 20.3 17 8.0 52 24.4 64 30 47 22.1 33 15.5 37.6
2006-2008 230 21.9 16 7.0 61 26.5 72 31.3 55 23.9 26 11.3 35.2
2009-2011 218 20.8 17 7.8 40 18.3 77 35.3 48 22.0 36 16.5 38.5
2012-2014 198 18.9 15 7.6 46 23.2 70 35.4 35 17.7 32 16.2 33.8
Ethnicity
European 793 75.6 69 8.7 204 25.7 283 35.7 158 19.9 79 10.0 <0.0001 29.9
Maori 194 18.5 7 3.6 34 17.5 47 24.2 55 28.4 51 26.3 54.6
Pacific 32 3.1 0 0.0 4 12.5 6 18.8 8 25.0 14 43.8 68.8
Others 30 2.9 5 16.7 8 26.7 13 43.3 4 13.3 0 0.0 13.3
Deprivation score (higher means greater deprivation)
1-2 127 12.1 7 5.5 40 31.5 47 37 21 16.5 12 9.4 0.2 26.0 0.002
3-4 119 11.3 14 11.8 31 26.1 37 31.1 18 15.1 19 16.0 31.1
5-6 245 23.4 18 7.3 62 25.3 84 34.3 52 21.2 29 11.8 33.1
7-8 285 27.2 20 7.0 67 23.5 91 31.9 62 21.8 45 15.8 37.5
9-10 272 25.9 22 8.1 49 18.0 90 33.1 72 26.5 39 14.3 40.8
Missing/unknown 1 0.1 0 0.0 1 100.0 0 0 0 0.0 0 0.0 0.0
Area of residence
Urban 614 58.5 52 8.5 143 23.3 197 32.1 131 21.3 91 14.8 0.2 36.2
Semi-urban or rural 406 38.7 29 7.1 94 23.2 144 35.5 89 21.9 50 12.3 34.2
Missing/unknown 29 2.8 0 0.0 13 44.8 8 27.6 5 17.2 3 10.3 27.6
Comorbidity (C3 index score)
0 912 86.9 75 8.2 226 24.8 312 34.2 187 20.5 112 12.3 0.05 32.8 <0.001
1 75 7.1 4 5.3 13 17.3 20 26.7 21 28.0 17 22.7 50.7
2 40 3.8 1 2.5 7 17.5 11 27.5 11 27.5 10 25.0 52.5
3+ 22 2.1 1 4.5 4 18.2 6 27.3 6 27.3 5 22.7 50.0
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Table 1 Patient characteristics by body mass index (BMI, kg/m2) groups (Continued)
Characteristics Total BMI < 21 BMI 21-24 BMI 25-29 BMI 30-34 BMI 35+ Chi-square % Obese Trend
N % N % N % N % N % N % p-value (BMI 30+) p-value
Screen-detected
Yes 303 28.9 17 5.6 57 18.8 117 38.6 72 23.8 40 13.2 0.02 37.0
No 746 71.1 64 8.6 193 25.9 232 31.1 153 20.5 104 13.9 34.5
Stage at diagnosis
I 147 14 15 10.2 38 25.9 47 32 28 19.0 19 12.9 0.5 32.0 0.06
II 537 51.2 34 6.3 137 25.5 186 34.6 114 21.2 66 12.3 33.5
III 309 29.5 25 8.1 67 21.7 97 31.4 70 22.7 50 16.2 38.8
IV 56 5.3 7 12.5 8 14.3 19 33.9 13 23.2 9 16.1 39.3
Grade
I 83 7.9 7 8.4 27 32.5 27 32.5 14 16.9 8 9.6 0.6 26.5 0.7
II 512 48.8 35 6.8 120 23.4 167 32.6 113 22.1 77 15.0 37.1
III 425 40.5 36 8.5 100 23.5 145 34.1 89 20.9 55 12.9 33.9
Missing/unknown 29 2.8 3 10.3 3 10.3 10 34.5 9 31.0 4 13.8 44.8
Histology
Ductal 898 85.6 71 7.9 214 23.8 295 32.9 188 20.9 130 14.5 0.5 35.4
Lobular 94 9 8 8.5 21 22.3 30 31.9 25 26.6 10 10.6 37.2
Other 57 5.4 2 3.5 15 26.3 24 42.1 12 21.1 4 7.0 28.1
ER/PR
ER+/PR+ 515 49.1 37 7.2 124 24.1 166 32.2 115 22.3 73 14.2 0.9 36.5
ER+/PR- 216 20.6 20 9.3 49 22.7 75 34.7 38 17.6 34 15.7 33.3
ER-/PR+ 22 2.1 2 9.1 5 22.7 6 27.3 5 22.7 4 18.2 40.9
ER-/PR- 270 25.7 20 7.4 64 23.7 92 34.1 62 23.0 32 11.9 34.8
Missing/unknown 26 2.5 2 7.7 8 30.8 10 38.5 5 19.2 1 3.8 23.1
HER-2
Positive 274 26.1 20 7.3 60 21.9 90 32.8 57 20.8 47 17.2 0.7 38.0
Equivocal 27 2.6 1 3.7 7 25.9 7 25.9 8 29.6 4 14.8 44.4
Negative 554 52.8 47 8.5 128 23.1 189 34.1 119 21.5 71 12.8 34.3
Missing/unknown 194 18.5 13 6.7 55 28.4 63 32.5 41 21.1 22 11.3 32.5
Primary treatment (RT = radiotherapy)
Breast conserving surgery with RT 451 43 29 6.4 99 22.0 152 33.7 111 24.6 60 13.3 0.1 37.9
Breast conserving surgery, no RT 45 4.3 3 6.7 17 37.8 15 33.3 6 13.3 4 8.9 22.2
Mastectomy with RT 379 36.1 33 8.7 93 24.5 124 32.7 69 18.2 60 15.8 34.0
Mastectomy, no RT 130 12.4 11 8.5 35 26.9 47 36.2 24 18.5 13 10.0 28.5
No primary surgery 44 4.2 5 11.4 6 13.6 11 25 15 34.1 7 15.9 50.0
Total breast conserving surgery 496 47.3 32 13.1 116 59.7 167 67.0 117 37.9 64 22.2 0.3 36.5
Total mastectomy 509 48.5 44 17.2 128 51.5 171 68.9 93 36.7 73 25.8 32.6
Total with RT 830 79.1 62 15.1 192 46.5 276 66.4 180 42.8 120 29.1 0.02 36.1
Total without RT 175 16.7 14 15.1 52 64.7 62 69.5 30 31.8 17 18.9 26.9
Facility where primary treatment was undertaken
Private 377 35.9 34 9.0 112 29.7 141 37.4 54 14.3 36 9.5 <0.0001 23.9
Public 672 64.1 47 7.0 138 20.5 208 31.0 171 25.4 108 16.1 41.5
Chi-sq P value based on table for each factor. Trend P value based on trend in proportion obese over ordered categories of factor
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Obesity was more frequent in screen-detected women.
By stage, 147 (14%) had stage 1 disease, 537 (51%) stage
2, 309 (30%) stage 3, and 56 (5%) stage 4. Obesity tended
to be greater in women with more advanced disease,
although this was not statistically significant (trend test
P=0.06; Table 1). BMI category was not significantly
related to other pathological features of grade, histology,
ER, PR, or HER-2 receptor status. For primary
treatment, obesity was not related to the use of breast
conserving surgery compared to mastectomy. Obese
patients were over-represented in women who had no
primary surgery, based on small numbers. Obese
patients were more likely to receive radiotherapy. Of the
1049 patients, 771 (68%) received chemotherapy and
hormonal therapy, and 338 (32%) received chemother-
apy alone.
Outcomes in relation to BMI (patients with chemotherapy)
Clinical outcomes were assessed for the first 10 years
after diagnosis, and for the whole follow-up period up to
14 years, comparing each group to those with BMI 21-
24 (Table 2 and Fig. 3). There was a trend in single-
factor (unadjusted) analysis for increased hazard ratios
(HR) in categories of obesity higher than the reference
group of BMI 21-24 , with HR’s for very obese women
being 1.28 for breast cancer deaths and 1.36 for total
mortality, for the whole follow up period. Underweight
women (BMI <21) also showed non-significant but
increased HRs for breast cancer mortality, overall
mortality, and recurrence in single factor analysis. These
results are also shown as cumulative incidence curves in
Fig. 3.
However, these associations were not significant and
disappeared when other factors were taken into account,
giving adjusted HRs for breast cancer-specific mortality
of 0.96, 95% confidence limits 0.56 to 1.69, and for total
mortality 1.03 (CI 0.63 to 1.67). There was no consistent
gradient of adjusted HRs with categories of obesity.
Obese women had a more elevated risk for deaths from
other causes, but this was not significant after control
for other factors (adjusted HR 1.55, limits 0.34 to 7.18).
For loco-regional and distant recurrence, there were
small increases in obese patients, but these were also not
significant. For underweight women, there were no sig-
nificant effects after controlling other factors. The pro-
portional hazards assumption was met for all outcomes
(Kolmogorov-type supremum test p-value > 0.05).
Subgroup analyses and quantitative analysis
Further analyses of 10 year breast cancer specific mortality
were carried out within subgroups of patients (Table 3),
specified by age, menopausal status, ethnic group (Maori,
Pacific Island, NZ European), stage (1+2, 3+4), systemic
treatment (chemotherapy and hormonal therapy, chemo-
therapy alone), mode of detection (screening, symptom-
atic), receptor status (ER and PR positive, ER and PR
negative, mixed), type of surgery (breast conservation,
mastectomy, no surgery), and post-operative radiotherapy
(yes, no). No significant and regular trends with BMI
(assessed in 3 categories) were seen in any of these sub-
group comparisons; in one subgroup, age 40-59, the differ-
ences were significant but there was no trend in mortality
with BMI category. Results for similar for total mortality
(data not shown).
Survival analyses were also done using obesity as a
continuous variable, excluding underweight patients, so
assessing if there was any trend with increasing BMI
above 21.0. For breast cancer specific mortality, the HR
after controlling other factors was 0.99 (95% limits 0.96-
1.02), and for overall mortality was 1.00 (0.97 to 1.03).
Analysis of outcomes in all patients
Survival analyses were also carried out for all 2296
patients, irrespective of treatment, who had available
data on BMI. No significant associations with BMI were
seen, assessed in 3 categories (Table 4). The hazard ratio
for the obese group (BMI 35+), compared to those with
BMI under 25, for breast cancer specific death over the
Fig. 2 Distribution of breast cancer patients by body mass index and ethnicity (n=1049). Maori and Pacific distributions significantly different from
NZ European (P< 0.001); see text
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Table 2 Hazard ratios for specific breast cancer outcomes by BMI groups in patients with chemotherapy or hormonal plus
chemotherapy (N=1049)
Outcome Follow-up period BMI (kg/m2) No of events Crude HR (95% CI) Adjusted HR (95% CI)
Breast cancer specific death 0-10 yrs <21 (N=81) 43 1.70 (0.99, 2.91) 1.13 (0.60, 2.14)
21-24 (N=250) 88 1.00 1.00
25-29 (N=349) 107 0.99 (0.66, 1.47) 0.96 (0.61, 1.51)
30-34 (N=225) 67 1.24 (0.82, 1.88) 0.98 (0.62, 1.54)
35+ (N=144) 49 1.31 (0.81, 2.12) 0.99 (0.57, 1.71)
Whole study period <21 44 1.66 (0.97, 2.84) 1.11 (0.59, 2.09)
21-24 91 1.00 1.00
25-29 110 0.98 (0.66, 1.46) 0.95 (0.61, 1.50)
30-34 67 1.21 (0.80, 1.83) 0.96 (0.62, 1.50)
35+ 49 1.28 (0.79, 2.07) 0.96 (0.56, 1.67)
Overall mortality 0-10 yrs <21 67 1.64 (0.98, 2.73) 1.12 (0.61, 2.05)
21-24 122 1.00 1.00
25-29 153 1.01 (0.69, 1.46) 0.92 (0.60, 1.41)
30-34 93 1.17 (0.79, 1.73) 0.88 (0.57, 1.34)
35+ 65 1.37 (0.88, 2.16) 1.05 (0.64, 1.73)
Whole study period <21 70 1.49 (0.89, 2.51) 1.04 (0.57, 1.90)
21-24 130 1.00 1.00
25-29 163 0.97 (0.68, 1.40) 0.87 (0.57, 1.32)
30-34 100 1.18 (0.81, 1.72) 0.89 (0.59, 1.33)
35+ 69 1.36 (0.87, 2.10) 1.03 (0.63, 1.67)
Death from other/unknown causes 0-10 <21 24 1.08 (0.22, 5.34) 1.44 (0.21, 9.97)
21-24 34 1.00 1.00
25-29 46 1.15 (0.41, 3.25) 1.11 (0.33, 3.72)
30-34 26 0.74 (0.21, 2.58) 0.74 (0.21, 2.67)
35+ 16 1.64 (0.50, 5.43) 1.55 (0.34, 7.18)
Whole study period <21 26 0.70 (0.14, 3.45) 1.01 (0.19, 5.45)
21-24 39 1.00 1.00
25-29 53 0.98 (0.39, 2.43) 0.78 (0.27, 2.29)
30-34 33 1.04 (0.40, 2.72) 1.15 (0.42, 3.11)
35+ 20 1.56 (0.54, 4.51) 1.42 (0.40, 5.01)
Loco-regional recurrence 0-5 <21 (N=81) 13 1.04 (0.22, 4.98) 1.24 (0.20, 7.64)
21-24 (N=250) 22 1.00 1.00
25-29 (N=349) 23 0.87 (0.32, 2.40) 1.13 (0.34, 3.73)
30-34 (N=225) 27 0.88 (0.28, 2.77) 1.38 (0.36, 5.29)
35+ (N=144) 11 0.60 (0.12, 2.87) 1.12 (0.16, 7.84)
Whole study period <21 17 1.58 (0.42, 6.02) 2.08 (0.42, 10.23)
21-24 25 1.00 1.00
25-29 25 1.11 (0.42, 2.93) 1.26 (0.41, 3.87)
30-34 28 1.10 (0.37, 3.28) 1.58 (0.44, 5.63)
35+ 12 0.63 (0.13, 3.04) 1.17 (0.19, 7.21)
Elwood et al. BMC Cancer  (2018) 18:76 Page 7 of 13
whole follow-up period was 1.06 (95% limits 0.80 to
1.46), and for total mortality was 0.96 (limits 0.75 to
1.21). There was an increased risk of loco-regional
recurrence in the first 5 years of follow up, but this was
not significant (hazard ratio 1.82, 95% limits 0.95 to
3.48). An analysis with BMI as a continuous variable also
showed no association.
Discussion
This group of breast cancer patients treated with
chemotherapy have a high prevalence of obesity (BMI
over 30), with 35% having a BMI of 30 or greater, and
14% a BMI of 35 or greater. There was no increase in
breast cancer mortality or in total mortality even in very
obese women; the hazard ratio (HR) for women with a
BMI of 35 or over, compared to those with BMI of 21-
24, for breast cancer mortality was 0.96, with 95% confi-
dence limits of 0.56 to 1.67, adjusted for other demo-
graphic and clinical factors; and for overall mortality, the
adjusted HR was 1.03 (95% limits 0.63 to 1.67). There
was no indication of a dose-response trend, either in the
main analysis or in subgroup analyses, or when assessing
BMI as a continuous variable throughout its range.
These results contrast with many other studies. A
meta-analysis of 82 studies showed an increased risk of
breast cancer mortality, HR 1.35 (95% limits 1.24-1.47)
for ‘obese’ women with a BMI over 30 compared to ’nor-
mal weight’ women with a BMI between 18.5 and 25 [1].
There was a slightly greater increase in total mortality, HR
1.41 (95% limits 1.29-1.53), due mainly to a substantial,
although non-significant, increase in cardiovascular mor-
tality (HR 1.60, 95% limits 0.66-3.87). However, as noted
earlier, the meta-analysis had evidence of publication bias,
with Egger’s test being significant (P=0.03) for the studies
of breast cancer mortality; the authors suggested that
“small studies with inverse results are missing”.
Our results suggest that the disadvantageous prognos-
tic effect of obesity reported elsewhere does not apply to
this breast cancer population treated with chemotherapy
in New Zealand. There is no clear explanation, apart
from chance variation, for the contrast between these
results and the results of the meta-analysis. Our data
were 98% complete and based on objective clinical
records after diagnosis and prior to systemic therapy. In
the meta-analysis [1] differences in outcomes between
obese and normal-weight women were similar for BMI
assessed pre-diagnosis and within 12 months after diag-
nosis. However, the excess risk in underweight women
was greater with post-diagnosis assessment. In the meta-
analysis [1], the association of BMI with total mortality
was stronger in pre-menopausal women (RR 1.75, limits
1.26-2.41) than in post-menopausal women (RR 1.34,
limits 1.26-2.41), but this heterogeneity was not statisti-
cally significant. Restriction of the data to invasive, early-
stage, or mammographically detected cases made little
difference to the results. In our analyses, we found no
associations within groups defined by menopausal status,
stage, method of detection, or other clinical or demo-
graphic variables.
The main analysis presented is based on a continuous
population-based clinical registry, but then restricted to
patients receiving chemotherapy. For these patients in-
formation on height and weight was fully recorded, with
98% completeness. The assessment was after diagnosis
and before systemic therapy was started. We are cau-
tious about the interpretation of results for patients who
did not receive chemotherapy, as there is substantial
missing data, but the results were similar, not showing
any association of breast cancer mortality or total
mortality with BMI. However, we have shown that the
missing data is not random, and is associated with
survival outcomes [35]. Another New Zealand study is
Table 2 Hazard ratios for specific breast cancer outcomes by BMI groups in patients with chemotherapy or hormonal plus
chemotherapy (N=1049) (Continued)
Outcome Follow-up period BMI (kg/m2) No of events Crude HR (95% CI) Adjusted HR (95% CI)
Distant metastasis 0-5 <21 43 1.74 (0.66, 4.54) 1.44 (0.51, 4.03)
21-24 90 1.00 1.00
25-29 103 1.13 (0.57, 2.24) 0.89 (0.44, 1.80)
30-34 65 1.20 (0.56, 2.55) 1.17 (0.51, 2.67)
35+ 62 1.62 (0.72, 3.64) 1.69 (0.69, 4.11)
Whole study period <21 46 1.62 (0.67, 3.93) 1.32 (0.52, 3.37)
21-24 103 1.00 1.00
25-29 127 1.38 (0.76, 2.53) 1.05 (0.56, 1.94)
30-34 87 1.50 (0.77, 2.90) 1.23 (0.61, 2.49)
35+ 70 1.73 (0.82, 3.63) 1.33 (0.61, 2.91)
‘Adjusted’ results from Cox regression model including BMI and ethnicity, menopausal status, age, social deprivation, urban-rural status, mode of diagnosis
(screening vs. symptomatic), year of diagnosis, stage, grade, histology, hormone receptor status (ER and PR), local treatment (surgery and radiotherapy),
systemic treatment (chemotherapy, hormonal therapy and biological treatment), treatment facility (public vs. private), comorbidity index
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(e)
Fig. 3 Cumulative incidence functions for breast cancer outcomes in five BMI groups: a breast cancer specific death, b overall mortality,
c death from other causes, d loco-regional recurrence, e metastasis. See Table 2 and text for related results
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hard to interpret as it is based on only 27% of eligible
patients because BMI data was not available on the
others [36].
Some other studies have also shown no association
with BMI. A study in Louisiana of 523 patients, not se-
lected on treatment, of whom 55% were obese (BMI >
30), showed no association with overall or disease-
specific survival, with a median follow-up of 49 months
[17]. The authors suggested that with the high preva-
lence of obesity in these centres, clinicians would be
more expert in dealing with obese patients and less
likely, for example, to undertreat with chemotherapy.
That would also apply in our population, where obesity
is a prominent and familiar issue. A large randomised
trial, the NSABP B-14 trial, showed no associations of
breast cancer mortality with BMI [9], and under-
treatment may be less likely in a trial. This trial of tam-
oxifen assessed 3385 women with node-negative, ER
positive breast cancer, with a median follow up of 166
months. Obese women did have a higher risk of contra-
lateral breast cancer incidence, other cancer incidence,
deaths from causes other than breast cancer, and total
mortality. In an analysis of 489 patients in three rando-
mised trials of chemotherapy for metastatic breast
cancer, there was no association between BMI and
progression-free or overall survival [37]. Obese patients
had a significantly improved progression-free survival in
a study restricted to women receiving upcapped doses of
chemotherapy [38]. A recent study showed more ad-
vanced staging in obese patients, but no significant effect
on survival [39]. The effects of obesity on survival may
only apply to certain subgroups. Thus, a study showed
no overall effect on survival or recurrence, although an
adverse outcome was seen in the subset of luminal A
cancers [40]. In another study, obesity was associated
with lower survival only in receptor positive tumours
with positive lymph nodes, while it was associated with
improved survival in receptor negative tumours [41]. A
Table 3 Subgroup analysis: breast cancer specific deaths by 10 years by BMI group and other factors
BMI <24 BMI 25-29.9 BMI 30+ P value
Total No. 331 349 369
Deaths 10 years, %
All patients 19.0 15.8 19.8 P value
Age <40 132 20.0 38.0 20.0 0.1
40-59 678 18.2 10.9 19.7 0.02
60+ 239 29.2 35.4 35.4 0.9
Menopause Pre-menopause 474 16.2 16.0 18.5 0.8
Peri-menopause 65 6.3 13.6 11.1 0.8
Post-menopause 506 23.9 15.9 22.3 0.2
Ethnicity* Maori 194 26.8 21.3 24.5 0.8
NZ European 793 18.7 15.6 17.3 0.6
Stage 1, 2 684 8.9 9.9 8.4 0.9
3, 4 365 40.2 27.6 38.0 0.1
Detection Screen detected 303 12.2 11.1 11.6 0.9
Symptomatic 746 21.0 18.1 23.4 0.4
Receptors ER+, PR+ 515 13.0 12.1 14.4 0.8
ER-, PR- 270 15.8 13.6 22.2 0.3
+/- 238 30.1 25.0 27.7 0.7
Systemic treatment Chemo only 338 33.0 24.1 32.8 0.2
Chemo + hormonal 711 12.4 11.6 13.8 0.8
Surgery Breast conserving surgery 496 14.2 11.4 9.9 0.5
Mastectomy 509 20.4 16.4 24.1 0.2
Radiotherapy RT 830 18.0 13.7 16.1 0.4
no RT 175 22.4 23.6 37.5 0.09
Health sector Public 672 22.2 16.4 20.4 0.3
Private 377 15.1 14.9 17.8 0.8
*Notes: Ethnicity: Pacific, Asian, Other, too few for separate assessment
P values from chi square value for each subgroup
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study of nearly 15,000 patients with pre-diagnostic BMI
data showed no associations between recurrence or mor-
tality in overweight women, and only a 10% increase in
risks in obese or in severely obese women [42]. However,
several more recent randomised trials of chemotherapy
have shown poorer outcomes in obese women; for
example [43–47].
BMI is a convenient and widely used measurement,
but other assessments of body size may be relevant. A
study of over 90,000 patients, assessed pre-diagnosis,
showed that mortality was related to greater triceps skin
fold thickness, but not to BMI [48]. In another study of
post-menopausal patients, weight, but not BMI, was
related to mortality [49]. Central obesity seems to have a
stronger impact on African American women than
general adiposity as measured by BMI [20].
BMI is related to many other lifestyle and dietary is-
sues. In a study of 9513 breast cancer patients, mortality
was related to low physical activity and to comorbidity,
but not to BMI [50], although in another study BMI but
not physical activity was related to increased breast can-
cer deaths [51]. In studies using pre-diagnosis dietary
data, mortality increased regularly with intake of fat [52]
in one study, and in another it increased with dietary
saturated fat, and decreased with higher beta-carotene
and vitamin A intakes [53].
Table 4 Hazard ratios by BMI groups in all patients with known BMI (n=2296)
Outcome Follow-up period BMI (kg/m2) Unadjusted HR (95% CI) Adjusted HR (95% CI)
Breast cancer specific death 0-10 <25 1.00 1.00
25-29 0.90 (0.70, 1.16) 0.98 (0.74, 1.30)
30+ 0.97 (0.76, 1.25) 1.10 (0.82, 1.46)
Whole study period <25 1.00 1.00
25-29 0.90 (0.70, 1.15) 0.97 (0.73, 1.29)
30+ 0.95 (0.74, 1.22) 1.06 (0.80, 1.41)
Overall mortality 0-10 <25 1.00 1.00
25-29 0.88 (0.71, 1.09) 1.03 (0.82, 1.30)
30+ 0.91 (0.74, 1.12) 0.96 (0.75, 1.22)
Whole study period <25 1.00 1.00
25-29 0.88 (0.72, 1.08) 1.01 (0.81, 1.26)
30+ 0.93 (0.76, 1.14) 0.96 (0.76, 1.21)
Death from other/unknown causes 0-10 <25 1.00 1.00
25-29 0.87 (0.59, 1.28) 0.97 (0.66, 1.45)
30+ 0.79 (0.53, 1.17) 0.84 (0.55, 1.29)
Whole study period <25 1.00 1.00
25-29 0.89 (0.62, 1.27) 0.98 (0.68, 1.41)
30+ 0.90 (0.63, 1.29) 0.96 (0.65, 1.42)
Loco-regional recurrence 0-5 <25 1.00 1.00
25-29 0.85 (0.42, 1.71) 0.80 (0.39, 1.67)
30+ 1.57 (0.85, 2.87) 1.82 (0.95, 3.48)
Whole study period <25 1.00 1.00
25-29 0.76 (0.40, 1.44) 0.74 (0.38, 1.44)
30+ 1.35 (0.77, 2.34) 1.48 (0.81, 2.68)
Distant metastasis 0-5 <25 1.00 1.00
25-29 0.95 (0.62, 1.46) 0.94 (0.60, 1.47)
30+ 1.15 (0.76, 1.75) 1.27 (0.81, 1.97)
Whole study period <25 1.00 1.00
25-29 1.12 (0.77, 1.62) 1.08 (0.74, 1.59)
30+ 1.33 (0.92, 1.91) 1.35 (0.92, 1.98)
‘Adjusted’ results from Cox regression model including BMI and ethnicity, menopausal status, age, social deprivation, urban-rural status, mode of diagnosis
(screening vs. symptomatic), year of diagnosis, stage, grade, histology, hormone receptor status (ER and PR), local treatment (surgery and radiotherapy), systemic
treatment (chemotherapy, hormonal therapy and biological treatment), treatment facility (public vs. private), comorbidity index
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Our study population has a substantial proportion of
women of Maori and Pacific Island ethnicity (2013 cen-
sus 22% and 4% respectively), the proportions in patients
treated with chemotherapy being 19% and 3%; but the
outcomes specific to these groups and to the majority
non-Maori non-Pacific group did not show associations
with BMI. A stronger effect of BMI on survival in breast
cancer has been suggested for women with Asian ances-
try, while effects in African Americans and Hispanics
were similar to non-Hispanic whites [20], based mainly
on US data. Our study population had a substantial fre-
quency of comorbidity, including diabetes, and diabetes
has been shown to be associated with a lower overall
survival in breast cancer patients [54]; in our study, haz-
ard ratios were not changed substantially by controlling
for comorbidity, but the numbers were too small to
assess effects specifically in those with diabetes.
Conclusions
In summary, in a population based series of women with
breast cancer in New Zealand, with 35% having a BMI
of 30 or greater, no association between BMI and overall
or breast cancer-specific survival, or disease-free
survival, was seen in patients receiving chemotherapy,
with 98% complete data on BMI; nor in all patients, irre-
spective of treatment, although for non-chemotherapy
patients there was substantial missing data. We have no
clear explanation, apart from chance variation, as to why
our results differ from some other studies, but it is im-
portant to document this difference, particularly as pre-
vious meta-analyses have shown some publication bias.
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